TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

OVERVIEW OF ACTIVITY
The past several years have seen an explosion in the emergence of new therapies that leverage the natural ability of the human body to attack and treat cancer. Known as cancer immunotherapies, these treatments are generating excitement all over the world as they have reshaped the management of lung cancer in previously unimagined ways. That being said, a number of controversies and questions remain with regard to the current application of these agents in clinical practice.

These proceedings from a satellite CME symposium held during the 2019 AACR Annual Meeting feature discussions with leading lung cancer investigators about the use of immunotherapy in the clinical care of patients with this disease. By providing information on important developments, this activity will assist medical oncologists and other healthcare professionals to address existing management uncertainties and determine the current and future roles of immune checkpoint inhibitors in lung cancer.

LEARNING OBJECTIVES

• Understand the biologic basis for the investigation of immune checkpoint inhibitors in combination with chemoradiation therapy for patients with nonmetastatic non-small cell lung cancer (NSCLC).
• Appreciate the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after concurrent chemoradiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
• Consider the available data and investigator perspectives regarding the efficacy of immune checkpoint inhibitors as single agents or in combination regimens for patients with metastatic NSCLC with or without targetable mutations.
• Recognize immune-related adverse events and other common side effects associated with the use of immune checkpoint inhibitors, and offer supportive strategies to minimize and manage these toxicities.
• Recall emerging data with novel approaches using immune checkpoint inhibitors for patients with NSCLC, and consider how these strategies may be applied in future clinical practice.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of an audio component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Advisory Committee and Consulting Agreements: AbbVie Inc, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Lilly, Merck, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantage Pharmaceuticals, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc, Incyte Corporation, Lilly, SWOG.

Vali A Papadimitrakopoulou, MD
Jay and Lori Eisenberg Distinguished Professor
Section Chief, Thoracic Medical Oncology
Professor of Medicine
Department of Thoracic/HN Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: AbbVie Inc, Araxes Pharma LLC, Arrys Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Gritstone Oncology, Guardant Health, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Nektar, Novartis, Takeda Oncology, Tesaro, TRM Oncology; Consulting Agreement: Leads Biolabs Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Guardant Health, Incyte Corporation, Janssen Biotech Inc, Lilly, Merck, Nektar, Novartis, Roche Laboratories Inc; Speaker/Preceptorship: Roche Laboratories Inc.

Naiyer Rizvi, MD
Price Family Professor of Medicine at CUMC
Columbia University Medical Center
Director, Thoracic Oncology Program
Co-Director, Immunotherapy in the Department of Medicine
Research Director, Price Family Comprehensive Center for Chest Care at NewYork-Presbyterian Hospital
New York, New York

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Lilly, Merck, NeoGenomics, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc; Stock Ownership: ARMO Biosciences, Bellicum Pharmaceuticals Inc, Gritstone Oncology.

David R Spigel, MD
Chief Scientific Officer
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Evelo Biosciences, Foundation Medicine, Genentech, GlaxoSmithKline, Illumina, Lilly, Merck, Moderna Therapeutics, Nektar, Novartis, Pfizer Inc, PharmaMar, Precision Oncology LLC, Roche Laboratories Inc, Takeda Oncology, TRM Oncology; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Aeglea BioTherapeutics, Amgen Inc, ARMO Biosciences, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Daiichi Sankyo Inc, EMD Serono Inc, Foundation Medicine, G1 Therapeutics, Genentech, GlaxoSmithKline, GRAIL, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Nektar, Neon Therapeutics, Novartis, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology, Tesaro, Transgene, University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: June 2019
Expiration date: June 2020